Effect of the Anti-C1s Humanized Antibody TNT009 and Its Parental Mouse Variant TNT003 on HLA Antibody-Induced Complement Activation-A Preclinical In Vitro Study

Overview

Journal Am J Transplant

Publisher Elsevier

Specialty General Surgery

Date 2017 Mar 3

PMID 28251805

Citations 9

Authors

M Wahrmann

J Muhlbacher

L Marinova

H Regele

N Huttary

F Eskandary

G Cohen

G F Fischer

G C Parry

J C Gilbert

S Panicker

G A Bohmig

Affiliations

Soon will be listed here.

Abstract

The classic pathway (CP) of complement is believed to significantly contribute to alloantibody-mediated transplant injury, and targeted complement inhibition is currently considered to be a promising approach for preventing rejection. Here, we investigated the mode of action and efficacy of the humanized anti-C1s monoclonal antibody TNT009 and its parental mouse variant, TNT003, in preclinical in vitro models of HLA antibody-triggered CP activation. In flow cytometric assays, we measured the attachment of C1 subcomponents and C4/C3 split products (C4b/d, C3b/d) to HLA antigen-coated flow beads or HLA-mismatched aortic endothelial cells and splenic lymphocytes. Anti-C1s antibodies profoundly inhibited C3 activation at concentrations >20 μg/mL, in both solid phase and cellular assays. While C4 activation was also prevented, this was not the case for C1 subcomponent attachment. Analysis of serum samples obtained from 68 sensitized transplant candidates revealed that the potency of inhibition was related to the extent of baseline CP activation. This study demonstrates that anti-C1s antibodies TNT009 and TNT003 are highly effective in blocking HLA antibody-triggered complement activation downstream of C1. Our results provide the foundation for clinical studies designed to investigate the potential of TNT009 in the treatment or prevention of complement-mediated tissue injury in sensitized transplant recipients.

Citing Articles

Torque Teno Virus Control by the Classical Pathway of Complement Activation-A Retrospective Analysis From a First-in-Human Trial Utilizing Sutimlimab.

Kapps S, Muhlbacher J, Kulifaj D, Courjal S, Eskandary F, Schiemann M J Med Virol. 2024; 96(11):e70039.

PMID: 39503157 PMC: 11600468. DOI: 10.1002/jmv.70039.

The Complement System as a Therapeutic Target in Retinal Disease.

Ong J, Zarnegar A, Selvam A, Driban M, Chhablani J Medicina (Kaunas). 2024; 60(6).

PMID: 38929562 PMC: 11205777. DOI: 10.3390/medicina60060945.

C1s targeting antibodies inhibit the growth of cutaneous squamous carcinoma cells.

Nissinen L, Riihila P, Viiklepp K, Rajagopal V, Storek M, Kahari V Sci Rep. 2024; 14(1):13465.

PMID: 38866870 PMC: 11169539. DOI: 10.1038/s41598-024-64088-3.

Sutimlimab for the Treatment of Cold Agglutinin Disease.

Berentsen S Hemasphere. 2023; 7(5):e879.

PMID: 37153870 PMC: 10155901. DOI: 10.1097/HS9.0000000000000879.

Cold Agglutinin Disease.

Gabbard A, Booth G Clin Hematol Int. 2021; 2(3):95-100.

PMID: 34595449 PMC: 8432332. DOI: 10.2991/chi.k.200706.001.

References

Golshayan D, Wojtowicz A, Bibert S, Pyndiah N, Manuel O, Binet I . Polymorphisms in the lectin pathway of complement activation influence the incidence of acute rejection and graft outcome after kidney transplantation. Kidney Int. 2016; 89(4):927-38. DOI: 10.1016/j.kint.2015.11.025. View

Bindon C, Hale G, Bruggemann M, Waldmann H . Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J Exp Med. 1988; 168(1):127-42. PMC: 2188986. DOI: 10.1084/jem.168.1.127. View

Loupy A, Hill G, Jordan S . The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol. 2012; 8(6):348-57. DOI: 10.1038/nrneph.2012.81. View

Sapir-Pichhadze R, Curran S, John R, Tricco A, Uleryk E, Laupacis A . A systematic review of the role of C4d in the diagnosis of acute antibody-mediated rejection. Kidney Int. 2014; 87(1):182-94. DOI: 10.1038/ki.2014.166. View

Schwaiger E, Wahrmann M, Bond G, Eskandary F, Bohmig G . Complement component C3 activation: the leading cause of the prozone phenomenon affecting HLA antibody detection on single-antigen beads. Transplantation. 2014; 97(12):1279-85. DOI: 10.1097/01.TP.0000441091.47464.c6. View

Venner J, Hidalgo L, Famulski K, Chang J, Halloran P . The molecular landscape of antibody-mediated kidney transplant rejection: evidence for NK involvement through CD16a Fc receptors. Am J Transplant. 2015; 15(5):1336-48. DOI: 10.1111/ajt.13115. View

Vo A, Zeevi A, Choi J, Cisneros K, Toyoda M, Kahwaji J . A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients. Transplantation. 2015; 99(2):299-308. DOI: 10.1097/TP.0000000000000592. View

Stegall M, Chedid M, Cornell L . The role of complement in antibody-mediated rejection in kidney transplantation. Nat Rev Nephrol. 2012; 8(11):670-8. DOI: 10.1038/nrneph.2012.212. View

Kulkarni S, Kirkiles-Smith N, Deng Y, Formica R, Moeckel G, Broecker V . Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial. Am J Transplant. 2016; 17(3):682-691. DOI: 10.1111/ajt.14001. View

10.

Thomas K, Valenzuela N, Gjertson D, Mulder A, Fishbein M, Parry G . An Anti-C1s Monoclonal, TNT003, Inhibits Complement Activation Induced by Antibodies Against HLA. Am J Transplant. 2015; 15(8):2037-49. PMC: 4654252. DOI: 10.1111/ajt.13273. View

11.

Visentin J, Guidicelli G, Couzi L, Merville P, Lee J, Di Primo C . Deciphering IgM interference in IgG anti-HLA antibody detection with flow beads assays. Hum Immunol. 2016; 77(11):1048-1054. DOI: 10.1016/j.humimm.2016.02.008. View

12.

Caliezi C, Wuillemin W, Zeerleder S, Redondo M, Eisele B, Hack C . C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev. 2000; 52(1):91-112. View

13.

Honger G, Krahenbuhl N, Dimeloe S, Stern M, Schaub S, Hess C . Inter-individual differences in HLA expression can impact the CDC crossmatch. Tissue Antigens. 2015; 85(4):260-6. DOI: 10.1111/tan.12537. View

14.

Shi J, Rose E, Singh A, Hussain S, Stagliano N, Parry G . TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. Blood. 2014; 123(26):4015-22. DOI: 10.1182/blood-2014-02-556027. View

15.

Derhaschnig U, Gilbert J, Jager U, Bohmig G, Stingl G, Jilma B . Combined integrated protocol/basket trial design for a first-in-human trial. Orphanet J Rare Dis. 2016; 11(1):134. PMC: 5050564. DOI: 10.1186/s13023-016-0494-z. View

16.

Chen G, Sequeira F, Tyan D . Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol. 2011; 72(10):849-58. DOI: 10.1016/j.humimm.2011.07.001. View

17.

Ricklin D, Reis E, Lambris J . Complement in disease: a defence system turning offensive. Nat Rev Nephrol. 2016; 12(7):383-401. PMC: 4974115. DOI: 10.1038/nrneph.2016.70. View

18.

Farrar C, Zhou W, Sacks S . Role of the lectin complement pathway in kidney transplantation. Immunobiology. 2016; 221(10):1068-72. DOI: 10.1016/j.imbio.2016.05.004. View

19.

Wahrmann M, Muhlbacher J, Marinova L, Regele H, Huttary N, Eskandary F . Effect of the Anti-C1s Humanized Antibody TNT009 and Its Parental Mouse Variant TNT003 on HLA Antibody-Induced Complement Activation-A Preclinical In Vitro Study. Am J Transplant. 2017; 17(9):2300-2311. PMC: 5600102. DOI: 10.1111/ajt.14256. View

20.

Viglietti D, Gosset C, Loupy A, Deville L, Verine J, Zeevi A . C1 Inhibitor in Acute Antibody-Mediated Rejection Nonresponsive to Conventional Therapy in Kidney Transplant Recipients: A Pilot Study. Am J Transplant. 2015; 16(5):1596-603. DOI: 10.1111/ajt.13663. View